Promising Survival in Patients with Recurrent Non-small Cell Lung Cancer Treated with Docetaxel and Gemcitabine in Combination as Second-Line Therapy Chao Hui Huang, MD, Michael M. Millenson, MD, Eric J. Sherman, MD, Hossein Borghaei, DO, David M. Mintzer, MD, Roger B. Cohen, MD, Arthur P. Staddon, MD, Judi Seldomridge, RN, BSN, Ocn Joseph Treat, MD, Holly Tuttle, RN, MSN, Karen J. Ruth, MS, Corey J. Langer, MD Journal of Thoracic Oncology Volume 3, Issue 9, Pages 1032-1038 (September 2008) DOI: 10.1097/JTO.0b013e31818307c2 Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions
FIGURE 1 Overall survival and EFS. Journal of Thoracic Oncology 2008 3, 1032-1038DOI: (10.1097/JTO.0b013e31818307c2) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions
FIGURE 2 EFS by time since TDx. Journal of Thoracic Oncology 2008 3, 1032-1038DOI: (10.1097/JTO.0b013e31818307c2) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions